Raghuram Selvaraju, chair of Relief Therapeutics, described the merger as “an exceptional opportunity to build a more resilient and innovative business.” Renexxion’s CEO Peter Milner echoed this sentiment, highlighting the combined potential to “redefine the landscape of gastrointestinal healthcare.”
Relief Therapeutics to merge with Renexxion : Path Forward and Regulatory Approval
The companies are targeting a definitive merger agreement by the end of December. Key steps include completing due diligence and securing approval from shareholders and regulators. The companies have not disclosed which regulatory bodies will oversee the merger.
If finalized, the merger will provide Relief Therapeutics with a larger drug pipeline and a stronger market position, positioning the company for further innovation in the treatment of complex diseases.
